UNSPSC 51113104: Ritrosulfan

This classification denotes an antineoplastic alkylating agent with the molecular formula C10H24N2O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YIY0662KX9, chemically known as 3,14-dioxa-2,15-dithia-6,11-diazahexadecane-8,9-diol, 2,2,15,15-tetraoxide, (r*,s*)- (9ci) but more generally known as ritrosulfan, which bears US NIH Compound Identifier 20107. European Medicines Agency schedules Ritrosulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10344MIG.

UNSPSC 51113104 Ritrosulfan is a Commodity code identifying a specific pharmaceutical product. The Texas Health and Human Services Commission's recent Request for Information (RFI) HHS0017013, posted April 3, 2026, solicits vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—indicating that state and local procurement under this code focuses on pharmaceutical supply chain arrangements, direct contracting with manufacturers, and prescription fulfillment efficiency rather than the product itself in isolation. The RFI seeks vendors experienced in direct contracting for self-insured employers and health plans, with flexibility to negotiate contracts using net pricing models without rebates and capacity to implement value-based or outcomes-based agreements. This signals that state and local governments use this code to manage pharmaceutical procurement channels, supplier relationships, and program design rather than to procure the specific drug substance in standard clinical or retail contexts.

State procurement activity under this code appears concentrated in Texas at the state health authority level. The RFI is preliminary market intelligence designed to inform future procurement strategy before a formal RFP is issued; no award value, budget range, set-aside designations, or temporal parameters are specified at this stage. The Texas HHS Commission's focus on direct-to-manufacturer relationships suggests potential future solicitations will address pharmacy benefit program modernization, cost management through alternative contracting models, and vendor qualifications for managing government employee and retiree prescription programs. The exploratory nature of the current RFI indicates limited near-term contract action, with formal competitive solicitations likely following vendor input on available solutions and implementation feasibility.